Back to search results

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Solid Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Site-113, Duarte, California, United States

  • Site-112, La Jolla, California, United States

  • Site-111, Palo Alto, California, United States

  • Site-114, Washington D.C., District of Columbia, United States

  • Site-103, Miami, Florida, United States

  • Site-105, Orlando, Florida, United States

  • Site-115, Tampa, Florida, United States

  • Site-110, Augusta, Georgia, United States

  • Site-109, Detroit, Michigan, United States

  • Site-101, St Louis, Missouri, United States

  • Site-117, New York, New York, United States

  • Site-116, Oklahoma City, Oklahoma, United States

  • Site-108, Philadelphia, Pennsylvania, United States

  • Site-107, Nashville, Tennessee, United States

  • Site-104, Dallas, Texas, United States

  • Site-106, West Valley City, Utah, United States

  • Site-102, Fairfax, Virginia, United States

Study leads

  • Chief Medical Officer

    Study Director

    Biohaven Pharmaceuticals, Inc.

View source on ClinicalTrials.gov(opens in a new tab)